Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00427154
Other study ID # NN1998-1540
Secondary ID
Status Terminated
Phase Phase 3
First received
Last updated
Start date January 10, 2007
Est. completion date March 11, 2008

Study information

Verified date September 2018
Source Novo Nordisk A/S
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial is conducted in the United States of America (USA). This trial will compare the changes in HbA1c after 26 weeks of inhaled insulin or rosiglitazone treatment, both in combination with metformin and glimepiride.


Description:

The decision to discontinue the development of AERx® is not due to any safety concerns. An analysis concluded that fast-acting inhaled insulin in the form it is known today, is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices.


Recruitment information / eligibility

Status Terminated
Enrollment 227
Est. completion date March 11, 2008
Est. primary completion date March 11, 2008
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Type 2 diabetes

- Currently treated with antidiabetes drugs (including Exenatide) for at least 2 months

- HbA1c between 7.5 and 11.0% (both inclusive) on antidiabetes combination therapy

- BMI less than or equal to 40 kg/m2

Exclusion Criteria:

- Current smoking or smoking within the last 6 months

- Current acute or chronic pulmonary disease (except for asthma)

- Proliferative retinopathy requiring acute treatment

- Clinically significant disease history including kidney or liver disease

- Heart disease which limits physical activity or results in discomfort with physical activity

- Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
rosiglitazone
Tablets, 4 mg once or twice daily.
inhaled human insulin
Treat-to-target dose titration scheme, inhalation.
metformin
Tablets, 2000 mg/day.
glimepiride
Tablets, 8 mg/day.

Locations

Country Name City State
United States Novo Nordisk Investigational Site Altoona Pennsylvania
United States Novo Nordisk Investigational Site Arlington Texas
United States Novo Nordisk Investigational Site Arlington Virginia
United States Novo Nordisk Investigational Site Asheville North Carolina
United States Novo Nordisk Investigational Site Athens Georgia
United States Novo Nordisk Investigational Site Atlanta Georgia
United States Novo Nordisk Investigational Site Atlanta Georgia
United States Novo Nordisk Investigational Site Augusta Georgia
United States Novo Nordisk Investigational Site Baltimore Maryland
United States Novo Nordisk Investigational Site Beaver Pennsylvania
United States Novo Nordisk Investigational Site Berlin New Jersey
United States Novo Nordisk Investigational Site Billings Montana
United States Novo Nordisk Investigational Site Boca Raton Florida
United States Novo Nordisk Investigational Site Boise Idaho
United States Novo Nordisk Investigational Site Charlotte North Carolina
United States Novo Nordisk Investigational Site Chattanooga Tennessee
United States Novo Nordisk Investigational Site Chattanooga Tennessee
United States Novo Nordisk Investigational Site Cherry Hill New Jersey
United States Novo Nordisk Investigational Site Chesterfield Missouri
United States Novo Nordisk Investigational Site Chicago Illinois
United States Novo Nordisk Investigational Site Cincinnati Ohio
United States Novo Nordisk Investigational Site Clarksville Tennessee
United States Novo Nordisk Investigational Site Clearwater Florida
United States Novo Nordisk Investigational Site Cleveland Ohio
United States Novo Nordisk Investigational Site Cleveland Ohio
United States Novo Nordisk Investigational Site Clinton Oklahoma
United States Novo Nordisk Investigational Site Colorado Springs Colorado
United States Novo Nordisk Investigational Site Concord California
United States Novo Nordisk Investigational Site Dallas Texas
United States Novo Nordisk Investigational Site Dallas Texas
United States Novo Nordisk Investigational Site Dayton Ohio
United States Novo Nordisk Investigational Site Dayton Ohio
United States Novo Nordisk Investigational Site Des Moines Iowa
United States Novo Nordisk Investigational Site Dunwoody Georgia
United States Novo Nordisk Investigational Site Escondido California
United States Novo Nordisk Investigational Site Fresno California
United States Novo Nordisk Investigational Site Greenville North Carolina
United States Novo Nordisk Investigational Site Greer South Carolina
United States Novo Nordisk Investigational Site Hialeah Florida
United States Novo Nordisk Investigational Site High Point North Carolina
United States Novo Nordisk Investigational Site Hollywood Florida
United States Novo Nordisk Investigational Site Honolulu Hawaii
United States Novo Nordisk Investigational Site Houston Texas
United States Novo Nordisk Investigational Site Hueytown Alabama
United States Novo Nordisk Investigational Site Huntington Beach California
United States Novo Nordisk Investigational Site Hurst Texas
United States Novo Nordisk Investigational Site Jackson Mississippi
United States Novo Nordisk Investigational Site Jefferson City Missouri
United States Novo Nordisk Investigational Site Kansas City Missouri
United States Novo Nordisk Investigational Site Kingsport Tennessee
United States Novo Nordisk Investigational Site La Jolla California
United States Novo Nordisk Investigational Site Lafayette Indiana
United States Novo Nordisk Investigational Site Lake Mary Florida
United States Novo Nordisk Investigational Site Las Vegas Nevada
United States Novo Nordisk Investigational Site Lawrenceville New Jersey
United States Novo Nordisk Investigational Site Lewisville Texas
United States Novo Nordisk Investigational Site Lexington Kentucky
United States Novo Nordisk Investigational Site Marianna Florida
United States Novo Nordisk Investigational Site Marlborough Massachusetts
United States Novo Nordisk Investigational Site Medford Oregon
United States Novo Nordisk Investigational Site Melbourne Florida
United States Novo Nordisk Investigational Site Merritt Island Florida
United States Novo Nordisk Investigational Site Miami Florida
United States Novo Nordisk Investigational Site Norfolk Virginia
United States Novo Nordisk Investigational Site Norristown Pennsylvania
United States Novo Nordisk Investigational Site Oklahoma City Oklahoma
United States Novo Nordisk Investigational Site Omaha Nebraska
United States Novo Nordisk Investigational Site Orange California
United States Novo Nordisk Investigational Site Ozark Alabama
United States Novo Nordisk Investigational Site Palm Harbor Florida
United States Novo Nordisk Investigational Site Pembroke Pines Florida
United States Novo Nordisk Investigational Site Peoria Illinois
United States Novo Nordisk Investigational Site Poway California
United States Novo Nordisk Investigational Site Powder Springs Georgia
United States Novo Nordisk Investigational Site Renton Washington
United States Novo Nordisk Investigational Site Richmond Virginia
United States Novo Nordisk Investigational Site Roseville California
United States Novo Nordisk Investigational Site Roswell Georgia
United States Novo Nordisk Investigational Site Sacramento California
United States Novo Nordisk Investigational Site Saint Louis Missouri
United States Novo Nordisk Investigational Site San Antonio Texas
United States Novo Nordisk Investigational Site San Diego California
United States Novo Nordisk Investigational Site Santa Barbara California
United States Novo Nordisk Investigational Site Scarborough Maine
United States Novo Nordisk Investigational Site Shawnee Mission Kansas
United States Novo Nordisk Investigational Site Springfield Illinois
United States Novo Nordisk Investigational Site Springfield Massachusetts
United States Novo Nordisk Investigational Site Staten Island New York
United States Novo Nordisk Investigational Site Suwanee Georgia
United States Novo Nordisk Investigational Site Syracuse New York
United States Novo Nordisk Investigational Site Tacoma Washington
United States Novo Nordisk Investigational Site Temecula California
United States Novo Nordisk Investigational Site Topeka Kansas
United States Novo Nordisk Investigational Site Tucker Georgia
United States Novo Nordisk Investigational Site Tucson Arizona
United States Novo Nordisk Investigational Site Tuscaloosa Alabama
United States Novo Nordisk Investigational Site Vero Beach Florida
United States Novo Nordisk Investigational Site Vestavia Hills Alabama
United States Novo Nordisk Investigational Site Walnut Creek California
United States Novo Nordisk Investigational Site Warrenton Virginia
United States Novo Nordisk Investigational Site Waterbury Connecticut
United States Novo Nordisk Investigational Site West Palm Beach Florida
United States Novo Nordisk Investigational Site Wichita Kansas

Sponsors (1)

Lead Sponsor Collaborator
Novo Nordisk A/S

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in HbA1c After 26 weeks
Secondary Fasting plasma glucose For the duration of the trial
Secondary Lipid profiles For the duration of the trial
Secondary Hypoglycaemic episodes For the duration of the trial
Secondary Glucose profiles For the duration of the trial
Secondary Change in body weight For the duration of the trial
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2